Australia has witnessed a dramatic transformation in ADHD medication prescribing patterns over the past decade. The data reveals significant shifts in who receives treatment, how they access it and what barriers remain. As of 2025, 2.36% of Australian adults were taking ADHD medicines, up from just 0.35% in 2016-17. This represents a nearly sevenfold increase in less than a decade. The demographic profile has also changed. Women are now more likely than men to take ADHD medicines, marking a notable shift in the patient population.
Effectiveness and Available Medications
Stimulant medications offer significant benefits for managing ADHD symptoms, with clinical evidence showing that 70-80% of children experience improvement with medication treatment. In Australia, the most commonly prescribed medications include lisdexamfetamine (Vyvanse), methylphenidate (Ritalin, Concerta) and dextroamphetamine. Non-stimulant options such as Intuniv and Strattera are also available for those who may not respond well to stimulants or have contraindications.
These medications work by improving focus, reducing impulsivity and helping individuals better control their behaviour. When properly prescribed and monitored, both stimulant and non-stimulant options provide clinically important benefits for children and adults.
The Shortage Crisis
Increased demand has created significant supply challenges. In 2022-2023, almost 470,000 Australians were prescribed ADHD medications (four times the number from nine years earlier). From January 2024 to May 2025, prescriptions filled increased by 60% for dexamfetamine, 88% for methylphenidate and 140% for lisdexamfetamine. This surge has contributed to nationwide shortages affecting methylphenidate (Concerta and Ritalin) that are expected to continue into late 2026. The shortage creates real problems for patients who depend on consistent medication access to manage their symptoms effectively.
PBS Subsidies and Cost Considerations
The Pharmaceutical Benefits Scheme (PBS) plays an important role in making ADHD medication affordable for many Australians. Without PBS subsidy, patients might pay more than $1,200 per year for ADHD medication treatment. With PBS coverage, the cost drops to $25.00 per prescription for eligible patients. In February 2021, Australia expanded PBS listing for lisdexamfetamine (Vyvanse) to allow use in adults with ADHD persisting from childhood, even when diagnosed after 18 years of age. This change removed previous age-of-diagnosis restrictions that had prevented many adults from accessing subsidised treatment.
Methylphenidate (Ritalin LA) has also been amended to allow access for adults with a retrospective diagnosis of ADHD. Around 20,000 patients who were previously paying full price can now access comparable treatments through PBS subsidies.
Access Barriers and Regional Inequality
The path to treatment involves more than just medication costs. The initial assessment process presents a significant financial barrier for many Australians. University of Wollongong research published in 2026 found that the average initial assessment for an adult ADHD diagnosis costs more than $530 without rebates. Total assessment costs averaged nearly $1,400 and reached almost $4,000 in some cases.
Geographic location also affects access. Medicine use was highest in Fremantle and Cottesloe in Western Australia, with ADHD prescriptions dispensed to 4.4% and 4.1% of adults, respectively, in 2023-24. Rates reached as low as 0.3% in Fairfield in Sydney’s southwest. This disparity suggests that financial and health system barriers may be preventing people from accessing the care they need.
Prescription Process and Multimodal Treatment
Initial diagnosis and prescription are generally restricted to psychiatrists or paediatricians. Once a patient’s condition is stable, general practitioners may take over prescribing responsibilities, depending on state and territory regulations. Australian clinical guidelines recommend medication as part of a multimodal approach. This means combining medication with psychological support, education and lifestyle changes for optimal results. The comprehensive approach recognises that medication alone may not address all aspects of ADHD management.
The Broader Impact
ADHD affects one in twenty Australians (approximately 1.2 million people). The condition is frequently misunderstood and undiagnosed. The social and economic costs of ADHD in Australia are estimated at $20.42 billion per year, or $25,071 per individual with ADHD per annum. These figures demonstrate the substantial societal burden and underscore the importance of effective treatment access. Improving access to diagnosis and treatment can reduce these costs while helping individuals manage their symptoms more effectively.
Moving Forward
The sharp rise in ADHD medication use reflects both increased awareness and improved diagnostic practices. It also highlights ongoing challenges around supply, affordability and equitable access. Addressing medication shortages, reducing assessment costs and ensuring consistent access across all regions remain important priorities for the Australian healthcare system. For individuals seeking treatment, understanding the available medications, PBS subsidies and prescription processes can help navigate the system more effectively. Working with healthcare providers who take a comprehensive, multimodal approach typically produces the best outcomes.
